All In MedTech

FDA Clearance Tracker · P860057-S220

PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 10, 2025

Approved

Time to decision

161 days

Received Oct 31, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P860057-S220
Device name
PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis
Applicant location
Irvine, CA
Received
Oct 31, 2024
Decided
Apr 10, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P860057

Device type

Device class
Class III
Regulation
21 CFR 870.3925

Every decision under product code DYE

FDA's approval statement

As written in FDA's record.

modifications to the Instructions for Use to reflect the 8-year findings of the Post-Approval Study (PAS) Report submitted for the long term follow-up of the PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis prospective cohort study

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.